AGS-003

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
012320112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The authors briefly highlight the results of targeted therapy and present new solutions in kidney cancer immunotherapy. The… (More)
Is this relevant?
2015
2015
BACKGROUND AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells… (More)
  • figure 1
  • table 2
  • table 1
  • table 3
  • figure 2
Is this relevant?
Review
2015
Review
2015
INTRODUCTION AGS-003 is a novel autologous dendritic cell vaccine currently in Phase III clinical development in combination with… (More)
Is this relevant?
Review
2015
Review
2015
Despite the renaissance of cancer immunotherapy, no novel immunotherapy has been approved for the treatment of renal cell cancer… (More)
Is this relevant?
2013
2013
357 Background: During the past decade, VEGF targeted therapies have become standard treatment for advanced RCC. While targeted… (More)
Is this relevant?
Review
2013
Review
2013
Immunotherapy with cytokines was the first effective treatment in metastatic renal cell carcinoma (mRCC). Long-term responders… (More)
Is this relevant?
2012
2012
348 Background: AGS-003 is a personalized immunotherapy that employs autologous DCs co-electroporated with the subject's… (More)
Is this relevant?
2012
2012
80 Background: AGS-003 is an autologous dendritic cell (DC) immunotherapy prepared from matured monocyte-derived DC co… (More)
Is this relevant?
Review
2012
Review
2012
Targeted therapy has survival benefit for patients with advanced renal cell carcinoma. However, intolerability often causes… (More)
Is this relevant?
2011
2011
2532 Background: Dendritic cells (DC) are a powerful tool for stimulating cell-mediated immunity through the effects of CD4+ and… (More)
Is this relevant?